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Epigenetics and cancerDiscovery of the enzymatic activity that catalyses oxidation of 5-methylcytosine (5mC) to generate 5-
hydroxymethylcytosine (5hmC) mediated by the MLL (KMT2A) fusion partner TET1 has sparked intense
research to understand the role this new DNA modiﬁcation has in cancer. An unambiguous picture has
emerged where tumours are depleted of 5hmC compared to corresponding normal tissue, but it is not
known whether lack of 5hmC is a cause or a consequence of tumourigenesis. Experimental data reveals
a dual tumour-suppressive and oncogenic role for TET proteins. Tet2mutations are drivers in haematological
malignancies but Tet1 had an oncogenic role in MLL-rearranged leukaemia, where Tet1 is overexpressed. Over-
expression of Tet2 in melanoma cells re-established the 5hmC landscape and suppressed cancer progression
but inhibiting Tet1 in non-transformed cells did not initiate cellular transformation. In this reviewwe summarise
recent ﬁndings that have shaped the current understanding on the role 5hmC plays in cancer.
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DNAmethylation became a cancer research focus in the 1970swhen
analysis of tumours revealed signiﬁcant aberrations in 5mC distribution,
i.e. hypermethylation of gene promoter CpG islands (or CGIs— genomic
regions with dense CG content), and gene silencing as a consequence,
against a background of genome-wide hypomethylation [1,2]. In somat-
ic cells DNA methylation occurs in CG dinucleotides and about 70–85%
of them are constantly methylated, with the exception of CGIs, which
tend to be demethylated. Methylation is catalysed by DNAmethyltrans-
ferases such as DNMT1, the maintenance methyltransferase, whichcopies methylation to the newly synthesised strand during cell division
and DNMT3A and DNMT3B, de novo methyltransferases — enzymes
that can methylate DNA in the absence of a hemimethylated template
[3]. This heritable epigenetic modiﬁcation present in all vertebrates is
needed for normal development as demonstrated in knockout mice
where functional loss of DNA methyltransferases is either early embry-
onic lethal (Dnmt1 and Dnmt3b) or perinatal lethal (Dnmt3a) [4,5]. Due
to the high rate of mutation of methylated CG due to spontaneous de-
amination to generate TG, the frequency of this CG dinucleotide in the
genome is signiﬁcantly reduced (about 4 fold) compared to other dinu-
cleotides such as GC. Although somatically methylated, the genome un-
dergoes global demethylation in early mammalian embryogenesis
(during germ cell differentiation and in the zygote), a process associated
with totipotency and pluripotency [6–8]. It has been a long-standing
Fig. 1. Distinct distribution patterns for Tet proteins and associated 5hmC loss upon Tet
downregulation. The highest density of Tet1 binding sites is located around the gene
promoter and loss of Tet1 leads to uniform decrease of 5hmC over the gene body and
promoter regions (green relative to the striped area). Loss of Tet2 in mouse embryonic
stem cells leads to 5hmC decrease over the gene body indicating speciﬁc targeting of
Tet2 to gene bodies.
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the break of the C\C bond between the cytosine ring and the methyl
group, often with claims of activities that proved to be difﬁcult to vali-
date independently [9].
One of the hypotheses for DNA demethylation involved oxidation of
5mC to 5hmC. 5hmC as a modiﬁed base had been previously identiﬁed
in mammalian tissues but ignored and forgotten largely due to contro-
versy [10]. In 2009, the presence of 5hmC was proven unequivocally
and the enzymatic process converting 5mC to 5hmC was identiﬁed
[11,12]. Compared to the relatively constant levels of 5mC in somatic
tissues (3–4% of total cytosines), 5hmC levels are signiﬁcantly lower
and vary greatly depending on the cell type (0.1%–0.7% of all cytosines)
[13,14]. The Tet family of Fe(II)- andα-ketoglutarate (α-KG) dependent
dioxygenases comprises three proteins (TET1, TET2, TET3) each with
varying abundance in different cell types. Tet1 and Tet2 are relatively
highly expressed in embryonic stem cells and early embryogenesis
and their levels drop as cells exit pluripotency and undergo differentia-
tion. Later in development Tet2 is highly expressed in the haematopoietic
systemwhile Tet3 is overexpressed in germ cells/oocyte, brain tissue and
more ubiquitously in somatic cells. TET proteins are responsible for
generating all of the 5hmC in the genome [15] and lack of all three TET
proteins is incompatible with proper development and such cells con-
tribute poorly to a developing embryo in chimera assays [16]. All three
proteins catalyse further oxidation steps generating 5fC and 5caC with
varying efﬁciencies [17,18]. The level of these intermediates is ~20
(5fC) and ~3 (5caC) in 106 cytosines per genome (or 0.002% 5fC/C and
0.0003% 5caC/C), at least two orders of magnitude fewer than 5hmC in-
dicating that these modiﬁcations could be true demethylation interme-
diates [18]. Both 5fC and 5caC can be excised by TDG [17,19], thus
closing the demethylation cycle [20,21]. Acute downregulation of TDG
activity generates up to 7 fold increase in 5fC in mouse embryonic
stem (ES) cells, indicating lack of excision of the oxidised 5hmC [22]. It
is thought that the main role of 5hmC lies in DNA demethylation but
5hmC is relatively stable and abundant in the genome (see Review by
Pfeifer and colleagues, this issue). The question thus arises, if TET pro-
teins are capable of iteratively oxidising 5mC to 5caC then why does
this reaction stop at 5hmC so frequently? Current data indicates that per-
haps 5hmC and other oxidised forms may have epigenetic roles other
than functioning as DNA demethylation intermediates (discussed
below). There is a possibility that differences among TET proteins
might be reﬂected by their demethylation potential since TET2 seems
to be somewhat more efﬁcient in generating 5fC and 5caC [18]. It is no-
table that the Tet2 gene region has undergone chromosomal inversion
and has lost its CXXC domain during evolution, a chromatin binding pro-
tein domain which is retained by both Tet1 and Tet3 [23]. The separated
region encodes a gene called Cxxc4 or IDAX and has been shown to reg-
ulate TET2 protein levels [23]. This is interesting since TET1 and TET2
are targeted to different sites in ES cells, and are thought to have different
functions in ES cells [24].
Before the discovery of TET enzymatic activity in 2009, Tet1 was
known as the fusion partner of MLL in patients with AML [25,26].
Later it was found that indirect inhibition of TET activity, particularly
in AML subclasses with mutations in metabolic enzymes (as discussed
below), correlated with promoter hypermethylation. This suggests
that lack of TET activity led to increasedmethylation and subsequent si-
lencing of the majority of genes affected [27,28]. Numerous loss-of-
function mutations of Tet2 have been identiﬁed in myeloid cancers
where Tet2 was shown to be a critical tumour suppressor as detailed
below. Nevertheless, it has been recently shown that Tet1 plays an on-
cogenic role in MLL-rearranged leukaemia where the endogenous Tet1
gene is directly targeted and overexpressed by the MLL fusion proteins
[29]. In this study Huang et al. showed in an MLL fusion-induced trans-
formation assay, that downregulation of Tet1 led to reversal of the
tumourigenic phenotype whereas overexpression of Tet1 exacerbated
it. These results suggest contradictory roles for TET proteins in cancer
initiation and progression but perhaps such behaviour is moreindicative of a mechanismwhere TET proteins are participating in rein-
forcing an existing cellular identity and transcriptional network. Never-
theless, it remains to be seen if aberrant targeting of TET proteins could
have a signiﬁcant role in cellular transformation.
2. Distribution and targeting of TET proteins and 5hmC
in development
It took over 50 years from the ﬁrst observation of 5hmC in bacterio-
phages to its recognition as a new epigeneticmodiﬁcation [30,31]. Com-
pared to 5mC which is relatively abundant in somatic tissues, absolute
levels of 5hmC are highly variable both in genome-wide and in speciﬁc
genomic single base locations and there seems to be no direct correla-
tion between 5mC levels and 5hmC [32]with the exception of complete
lack of 5mC where no 5hmC is generated, as detailed below. This is in-
dicative of a highly controlled targeting mechanism of functional TET
proteins to the chromatin to generate the 5hmC patterns observed,
mechanisms that might be speciﬁc to a particular cellular state [33].
Moreover, this control is exerted differentially among the three TET pro-
teins as evidenced by a series of recent observations. In ES cells, associ-
ation of TET1 to the chromatin is stronger than that of TET2,which could
be explained by the lack of the CXXC domain [34]. Also, TET1 and TET2
are targeted to different genomic regions in ES cells,where TET1 ismore
associated with promoters while TET2 regulates oxidation of gene
bodies as shown in Fig. 1 [24]. Interestingly, Huang et al. found that
loss of Tet2 has a more dramatic effect on global 5hmC loss in both
Tet2 shRNA depleted and Tet2−/− ES cells, even though it is known
that the expression level of Tet2 is lower in ES cells than that of Tet1
[15]. This study also showed that different regions are affected in
shRNA treated ES cells: while Tet1 shRNA affected mainly promoter re-
gions, loss of Tet2 resulted in signiﬁcant loss of 5hmC in gene bodies and
at the boundaries of highly expressed exons [24].
One interesting aspect of the abundance of 5mC and 5hmC in adult
tissues is that while the majority of somatic cells have relatively
constant 5mC levels, cells in the adult stem cell compartment have
signiﬁcantly lower levels for both modiﬁcations, therefore it is thought
that the presence of 5hmC in healthy tissues is an indication of the
differentiation state, with more differentiated cells having more 5hmC
and a tissue speciﬁc 5hmC level [35,36].
3. Modulation of TET activity by cofactors and vitamins
TET proteins are dioxygenases that usemolecular oxygen, Fe(II) and
2-oxoglutarate to oxidise 5mC and convert it to 5hmC. 2-Oxoglutarate
(2OG also known as α-ketoglutarate) is a cofactor produced in the
Krebs cycle by isocitrate dehydrogenase (IDH1/2/3) through
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roles and locations (IDH1 is cytosolic and IDH2 is mitochondrial)
and the importance of these proteins in epigenetic homeostasis is
highlighted in gain of function mutations (such as IDH1 R132) which ca-
talyses a neomorphic reaction that converts 2OG to 2-hydroxyglutarate
(2HG). 2HG inhibits the catalytic activity of 2OG dependent dioxygenases
including TET proteins [28]. Gain-of-function mutations in IDH1 are
frequent in cancer as detailed below but since 2OG affects many other
epigenetic regulators such as lysine demethylases, subsequent
tumourigenic events might be multifactorial and not necessarily
TET activity related.
Vitamin C is an essential nutrient for primates (including humans),
bats and guinea pigs, which have lost the ability to synthesise it from
glucose, unlike most mammals which can synthesise Vitamin C. Recent
studies have shown that Vitamin C can enhance DNA demethylation
through an increase in TET activity [37,38]. This is possible because Vita-
min C acts as an electron donor and recycles the oxidation state of Fe(IV)
to Fe(II) therefore adjusting the redox state of iron containing enzymes
for subsequent oxidation reactions. In the absence of a substrate (5mC),
decarboxylation of 2OG to succinate will lead to inactive TET enzyme
with Fe(IV) which can be reduced to Fe(II) by Vitamin C and render
the enzyme active again.Fig. 2. Dual, cancer-speciﬁc functions for TET proteins and 5hmC levels in differentiation
stages of adult stem cells. The abundance of 5hmC is low in differentiated adult stem
cells and increases over the course of differentiation (intensity of the colour in the nuclei
representing 5hmC levels throughout). Cellular transformation can occur through various
mechanisms and depending on the type of cancers Tet proteins can have both tumour
suppressive or oncogenic roles. Low 5hmC containing melanoma cells can become less
tumourigenic by overexpression of Tet2 which also leads to increased 5hmC. MLL-fusion
leukemic cells become less tumourigenic upon Tet1 downregulation which leads to
decrease of 5hmC overall.4. Mechanism of 5hmC loss in cancer
5mC is the only substrate to generate 5hmC in vivo as evidenced
by measuring absolute 5hmC levels in ES cells lacking all three DNA
methyltransferases and 5mC as a result [14,39]. In the absence of all
DNMTs 5hmC levels are below detection limits, but in cells with nor-
mally distributed 5mC throughout the genome, 5hmC levels are
highly variable and its level and distribution are cell type speciﬁc
[33].
Genomic hypomethylation is a key feature in cancer [1,2]. Research
for more than a decade has resulted in a more comprehensive picture
of DNA demethylation and we now know that loss of methylation can
occur through various mechanisms: active loss through iterative oxida-
tion of 5mC to 5hmC, 5-formylcytosine (5fC) and 5-carboxycytosine
(5caC) by TET proteins followed by excision of 5fC and 5caC by TDG
[20]; active loss through deamination of 5mC to U catalysed by AID
(AICDA) and APOBEC1 followed by base excision repair [6]; passive
loss whereby methylation is diluted during several cycles of cell divi-
sions in the context of lack of maintenance activity by DNMT1 and its
partner UHRF1 [40]. It has been recently conﬁrmed that at least in the
case of primordial germ cells (PGCs) passive demethylation is the dom-
inant mechanism to demethylate the genome in combination with ac-
tive removal of 5mC through iterative oxidation by TET proteins and
replicative loss of both 5mC and 5hmC [41–44]. In cellswith a functional
maintenance methylation system, an accelerated passive demethyla-
tion can exist whereby the oxidised 5mC is lost during DNA replication
since 5hmC is not recognised by Dnmt1 [45] (see also Review by
Hajkova and colleagues, this issue).
Loss of 5hmC in tumours, as discussed below, can occur through
two mechanisms reported to date: inactivating mutations of Tet and
inhibition of TET activity through IDH1/2 mutations [27,28,46,47].
This might be cancer type speciﬁc since many solid cancers do not
show mutations in either of these genes. Very few cancers exhibit
mutations in Dnmt1 [48] and therefore loss of the substrate 5mC
through Dnmt1 inactivation is not considered to be a signiﬁcant
route to initiating tumourigenesis. Nevertheless, numerous muta-
tions in Dnmt3a have been identiﬁed in blood cancers as described
in more details below.
Loss of TET activity is associated with the cancer phenotype but
it is not clear whether TET proteins function as tumour suppressors
or oncogenes. While loss of Tet1 and Tet2 expression is associated
with solid cancers, implying a tumour suppressor role, in the contextof genomic rearrangements such as in MLL-fusion rearranged leukae-
mia, Tet1 exhibits a clear oncogenic role (Fig. 2) [29].
4.1. Loss of 5hmC in solid cancers
Anumber of studies have revealed signiﬁcantly lower 5hmC levels in
cancer cell lines [32] or primary tissue, melanoma [49], adenoma and
carcinoma [50] compared to the normal surrounding tissue. It is impor-
tant to highlight that cell culture conditions and the transition from a
primary tissue towards establishing a cell line can inﬂuence the levels
of 5hmC, which is also associated with strong reduction of Tet expres-
sion [32].
Changes in expression of Tet1 have been reported in solid cancers,
where Tet1was downregulated while Tet2 and Tet3 expression did not
show differences compared to normal tissues [32]. Other labs have
found strong reduction in Tet1 expression and signiﬁcant reduction in
Tet2 and Tet3 in breast and liver cancers, which could explain the low
levels of 5hmC [49–52]. Kudo et al. found that reduction of Tet1/2/3 ex-
pression and subsequently of 5hmC levels was a consequence of BRAF
V600E oncogene driven cellular transformation in NIH3T3 cells [53]
and excluded the possibility that activation of the MAPK pathway was
causing Tet1 downregulation. Importantly, this study showed that
downregulation of Tet1 using stably integrated shRNA in NIH3T3 cells
was not sufﬁcient to induce cellular transformation [53]. This could in-
dicate that loss of 5hmC probably does not have driver properties in
cancer initiation but rather reinforces the molecular networks
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consequence of global 5mC loss in cancers. However, colon and prostate
adenocarcinoma showed onlymodest global reduction compared to the
loss of 5hmC therefore this cannot account for lower 5hmC seen in these
cancers [35].
Very few studies have mapped 5hmC distribution in cancer tissues.
Melanoma is associated with strong reductions in absolute 5hmC levels
[49] and sequencing of the 5hmC landscape validated wide-spread loss
of 5hmC in the genome and revealed increase in 5mC, as a consequence
of lack of oxidation, in numerous gene bodies (of genes in Wnt sig-
nalling melanogenesis pathways) and promoters (of genes involved
in regulation of cell morphogenesis, cytoskeleton organisation etc.).
Another report in pancreatic cancer cells found that global loss
of 5hmC was accompanied by genomic redistribution of the modiﬁ-
cation where exons and transcription factor binding sites were
enriched for 5hmC compared to normal cells and this enrichment
was more variable in promoters, CpG islands and shores in the two
cell lines analysed [54].
4.2. Loss of 5hmC in haematological malignancies
Although Tet1 was ﬁrst identiﬁed as one of the MLL fusion partners
in leukaemias, it shows the highest expression levels in embryonic stem
cells and in early embryogenesis. Tet2 expression is the highest in the
haematopoietic lineage where it is thought to be involved in normal
haematopoiesis, exit of haematopoietic stem cells (HSC) from the
multipotent niche and lineage determination. A number of Tet2 knock-
out mouse lines have been generated and the overall conclusion is that
Tet2 is not essential for normal development as it is not embryonic le-
thal, but mice lacking Tet2 develop haematopoietic malignancies with
phenotypes similar to human CMML (chronic myelomonocytic leukae-
mia) patients with mutant Tet2 [55]. Tet2−/− HSCs are skewed to-
wards an undifferentiated state with increased ability to repopulate
the haematopoietic compartment during competitive reconstitution
assays with normal Tet2+/+cells. Interestingly, this phenotype is
similar to conditional Dnmt1−/− and Dnmt3a −/− HSC, which
are also not able to differentiate during serial transplantation assays
[56,57]. This strengthens the hypothesis whereby lineage determi-
nation in the haematopoietic system is controlled in part by deposi-
tion of 5mC and 5hmC, with the principal role being to silence genes
used by differentiatedmyeloid lineages [58]. Hence the number of HSCs
in Tet2−/−mice is increased and although they can differentiate some-
what, the lineage is skewed towards monocyte/macrophage cell fates
[55,59–61].
Numerous Tet2mutations have been identiﬁed inmyeloproliferative
neoplasm (MPN), myelodysplastic syndrome (MDS) and other blood
cancers [46,62–65], also reviewed in [66]. About 15% of myeloid cancers
and 22% of AML have Tet2 inactivating mutations [46,63] and in AML
with normal karyotype (CN-AML) which accounts for 40–50% of cases,
mutations in other epigenetic regulators such as EZH2, DNMT3a, TET2,
MLL, IDH1 and IDH2 are common. A key question in the case of TET pro-
teins is whether it is the 5hmC generated by the protein, or some differ-
ent functions of the protein itself that has tumour suppressive roles. To
answer this question, one needs to separate the oxidative from the non-
oxidative roles of TET proteins. Ko et al. partially addressed this question
by analysing myeloid malignancies and the associated 5hmC levels in
the context of wild-type or mutant Tet2 [67]. Within the Tet2mutated
group where low 5hmC levels were measured, a number of cases
fortuitously contained missense mutations in amino acids involved
in various aspects of the 5hmC generating TET enzymatic activity
with otherwise normal protein sequence [67]. This indicates that
in at least some haematological malignancies, the tumour suppres-
sive role of TET2 appears to be correlated to its oxidative activity. A
more elegant demonstration of this would be to generate transgenic
mice with Tet2 missense mutations in amino acids involved in oxi-
dative activity, thus providing a causal link between tumoursuppression and TET2 oxidative activity, which has not been report-
ed to date to our knowledge.
5. 5hmC maintenance through cell division
There is no evidence so far that 5hmC is maintained through cell di-
vision. Moreover, there is in vitro evidence that DNMT1 does not recog-
nise hemihydroxymethylated DNA to methylate the opposite strand
[68]. Therefore, generation of 5hmC can induce 5mC loss during cell di-
vision. Combined with subsequent oxidation steps of 5hmC, removal of
5fC and 5caC by TDG is considered to accelerate global demethylation
through an active–passive demethylation mechanism [20]. Neverthe-
less, in certain cell types, particularly with an apparently intact or par-
tially functional methylation system, 5hmC might have a role for
deposition of 5mC through an unknownmechanism. This is highlighted
by observations that while some genomic regions (such as promoters)
accumulate 5mC upon Tet2 knockdown in ES cells, the vast majority of
regions lost both 5hmC and 5mC [24]. In addition, regions such as IAPs
(intracisternal A particles) that do not demethylate in ES cells when
they are transiting to ground state pluripotency, do accumulate a
small amount of 5hmC, but do not demethylate over time [45]. Similar
observations have been reported in imprinted control regions and loci
escaping reprogramming in PGCs [42,69]. It has been argued that loss
of 5hmC through cell division is associated with, and could be caused
by, rapid replication cycles in highly proliferating cells [30]. While this
is a possibility in primary cell lines expanded in culture [32], mouse ES
cells are highly proliferating in culture and maintain a relatively high
level of 5hmC over time therefore it does not support this hypothesis.
6. Reading 5hmC, 5fC and 5caC (5oxiC)
After the discovery of 5hmC, the most studied hypothesis was that
5hmC is an intermediate in the demethylation pathway. This has been
validated in various systems, although research has highlighted that it
is likely that 5hmC has its own bona ﬁde epigenetic functions (see
Review by Pfeifer and colleagues, this issue). First, if 5hmCwas an inter-
mediate only in the demethylation cycle, its levels probably would be
signiﬁcantly lower in the genome. Second, known methyl binders [70]
do not recognise 5hmC, therefore local oxidation of 5mC could lead to
release of these proteins from chromatin. Third, as recent work shows,
even though knockout of all three TET proteins leads to some increase
inmethylation, it does not steadily increase to saturation ofmethylation
in the genome.
A number of labs have attempted to ﬁnd “readers” for the oxidated
forms of 5mC, proteins that would recognise and bind to 5oxiC. The
ﬁrst identiﬁed was UHRF1 (known as NP95), which is the protein that
recognises 5mC at DNA replication and recruits DNMT1 to methylate
the newly synthesised strand. It was shown that UHRF1 recognises
5hmC [71] but the function of this binding is not known, especially
since DNMT1 does not recognise hemihydroxymethylated DNA to
methylate the opposite strand as it does with hemimethylated DNA
in vitro [68]. On the other hand, a similar protein UHRF2 was found
to bind to 5hmC [72] and it will be exciting to ﬁnd out if certain re-
gions in the genome could use an alternative mechanism tomaintain
5hmC.
Later, MBD3was reported to bind to 5hmC [73] but this was not val-
idated by other studies [72,74]. The most comprehensive study so far is
by Spruijt et al., where a sensitive SILAC based proteomics approachwas
used to identify 5oxiC binders. This led to interesting results and identi-
ﬁed a number of 5oxiC “readers” [72]. A similar studywhich used longer
promoter sequences as bait [74] followed by proteinmass spectrometry
highlighted something unexpected. It found that 5fC was recognised
uniquely by a higher number of proteins compared to a very few iden-
tiﬁed as 5hmC binders [74]. Moreover, there was a strong enrichment
for transcription factors such as Fox domain transcription factors and
the complete NURD complex. Interestingly this pattern was DNA
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cantly to 5fC DNA depending on the bait. It is possible that only a subset
of the proteins bound directly, suggested by an independent method
used to validate the 5fC binders [74]. It remains to be seen if 5fC can func-
tion as a repressive or potentially activating epigenetic modiﬁcation.7. Outlook
Understanding the molecular events that drive cellular transforma-
tion is essential in order to develop effective cancer therapies. Epigenet-
ic aberrations such as promoter hypermethylation are frequent in
tumours and since the discovery of the demethylation mechanism
through iterative oxidation of 5mC to generate 5hmC, 5fC and 5caC
and recycle C, great attention has been given in understanding the
demethylating role of 5hmC in cancer. There have been a series of excit-
ing studies published recently, which answered some of the questions
and led to novel diagnostic avenues. There is a strong correlation
between loss of 5hmC and cancer development but research to date in-
dicates that it is more likely that TET proteins are reinforcing themolec-
ular circuitries already present in cancer cells, rather than contributing
to cellular transformation through loss of TET activity. TET2 in the
haematopoietic system is an exception since results in Tet2 deﬁcient
mice demonstrated that loss of Tet2 is sufﬁcient to induce neoplasm,
therefore Tet2 functions as a bona ﬁde tumour suppressor [55,59,60].
Since Tet1 can have an oncogenic role in MLL-rearranged leukaemia,
and lack of oxidation leads to hypermethylation of cancer-relevant
sub-classes of genes in melanoma, a key interest for the future would
be to know more about how TET proteins are targeted to chromatin
and what molecules control this. The observation that overexpression
of the Yamanaka pluripotency factors can lead to wide-spread tumour
formation in vivo [75], all in the absence of geneticmutations, highlights
the fact that epigenetic reprogramming can drive cellular transforma-
tion. Indeed, one component of epigenetic reprogramming is global
DNA demethylation, a feature frequently observed in cancer together
with hypermethylation of CGI promoters. Therefore, understanding
targeting of the DNA methylation machinery, in addition to targeting
of TET proteins, is a key question to address in the future.References
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